Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy

R. Corvo, G. Sanguineti, M. Scala, G. Garaventa, A. Santelli, M. Barbieri, V. Vitale

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims and background: The purpose of this phase II study was to assess the efficacy and toxicity of an accelerated radiotheraphy schedule with the concomitant boost technique in the management of patients with advanced head and neck squamous cell carcinomas (HN-SCC) of various primary sites. Methods: From May 1989 to December 1992 45 patients were scheduled to receive a total dose of 75 Gy in 40 fractions over 40 days. The boost encompassing the macroscopic disease was given as a second daily dose during the last 2 weeks of the basic treatment. Results: Severe mucositis was recorded in 27 (60%) patients. Late side effect occurred in 2. As regards local control the primary tumor site was the most significant prognostic factor: at a median follow-up of 24 months (range 12-52 months) the actuarial local control rate was 79%, 48% and 15% for oronasopharyngeal, laryngohypopharyngeal and oral cavity primary sites, respectively (p = 0.004). Conclusions: This high dose concomitant boost regimen appears feasible in advanced HN-SCC. However, our results indicate the primary tumor site as a major prognostic factor even with an accelerated treatment schedule.

Original languageEnglish
Pages (from-to)135-138
Number of pages4
JournalTumori
Volume80
Issue number2
Publication statusPublished - 1994

Fingerprint

Neck
Radiotherapy
Head
Appointments and Schedules
Neoplasms
Mucositis
Mouth
Therapeutics
Carcinoma, squamous cell of head and neck

Keywords

  • concomitant boost radiotherapy
  • head and neck tumors
  • primary site

ASJC Scopus subject areas

  • Cancer Research

Cite this

Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy. / Corvo, R.; Sanguineti, G.; Scala, M.; Garaventa, G.; Santelli, A.; Barbieri, M.; Vitale, V.

In: Tumori, Vol. 80, No. 2, 1994, p. 135-138.

Research output: Contribution to journalArticle

Corvo, R. ; Sanguineti, G. ; Scala, M. ; Garaventa, G. ; Santelli, A. ; Barbieri, M. ; Vitale, V. / Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy. In: Tumori. 1994 ; Vol. 80, No. 2. pp. 135-138.
@article{b269412cda5e40afb6a5411ee03debbf,
title = "Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy",
abstract = "Aims and background: The purpose of this phase II study was to assess the efficacy and toxicity of an accelerated radiotheraphy schedule with the concomitant boost technique in the management of patients with advanced head and neck squamous cell carcinomas (HN-SCC) of various primary sites. Methods: From May 1989 to December 1992 45 patients were scheduled to receive a total dose of 75 Gy in 40 fractions over 40 days. The boost encompassing the macroscopic disease was given as a second daily dose during the last 2 weeks of the basic treatment. Results: Severe mucositis was recorded in 27 (60{\%}) patients. Late side effect occurred in 2. As regards local control the primary tumor site was the most significant prognostic factor: at a median follow-up of 24 months (range 12-52 months) the actuarial local control rate was 79{\%}, 48{\%} and 15{\%} for oronasopharyngeal, laryngohypopharyngeal and oral cavity primary sites, respectively (p = 0.004). Conclusions: This high dose concomitant boost regimen appears feasible in advanced HN-SCC. However, our results indicate the primary tumor site as a major prognostic factor even with an accelerated treatment schedule.",
keywords = "concomitant boost radiotherapy, head and neck tumors, primary site",
author = "R. Corvo and G. Sanguineti and M. Scala and G. Garaventa and A. Santelli and M. Barbieri and V. Vitale",
year = "1994",
language = "English",
volume = "80",
pages = "135--138",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy

AU - Corvo, R.

AU - Sanguineti, G.

AU - Scala, M.

AU - Garaventa, G.

AU - Santelli, A.

AU - Barbieri, M.

AU - Vitale, V.

PY - 1994

Y1 - 1994

N2 - Aims and background: The purpose of this phase II study was to assess the efficacy and toxicity of an accelerated radiotheraphy schedule with the concomitant boost technique in the management of patients with advanced head and neck squamous cell carcinomas (HN-SCC) of various primary sites. Methods: From May 1989 to December 1992 45 patients were scheduled to receive a total dose of 75 Gy in 40 fractions over 40 days. The boost encompassing the macroscopic disease was given as a second daily dose during the last 2 weeks of the basic treatment. Results: Severe mucositis was recorded in 27 (60%) patients. Late side effect occurred in 2. As regards local control the primary tumor site was the most significant prognostic factor: at a median follow-up of 24 months (range 12-52 months) the actuarial local control rate was 79%, 48% and 15% for oronasopharyngeal, laryngohypopharyngeal and oral cavity primary sites, respectively (p = 0.004). Conclusions: This high dose concomitant boost regimen appears feasible in advanced HN-SCC. However, our results indicate the primary tumor site as a major prognostic factor even with an accelerated treatment schedule.

AB - Aims and background: The purpose of this phase II study was to assess the efficacy and toxicity of an accelerated radiotheraphy schedule with the concomitant boost technique in the management of patients with advanced head and neck squamous cell carcinomas (HN-SCC) of various primary sites. Methods: From May 1989 to December 1992 45 patients were scheduled to receive a total dose of 75 Gy in 40 fractions over 40 days. The boost encompassing the macroscopic disease was given as a second daily dose during the last 2 weeks of the basic treatment. Results: Severe mucositis was recorded in 27 (60%) patients. Late side effect occurred in 2. As regards local control the primary tumor site was the most significant prognostic factor: at a median follow-up of 24 months (range 12-52 months) the actuarial local control rate was 79%, 48% and 15% for oronasopharyngeal, laryngohypopharyngeal and oral cavity primary sites, respectively (p = 0.004). Conclusions: This high dose concomitant boost regimen appears feasible in advanced HN-SCC. However, our results indicate the primary tumor site as a major prognostic factor even with an accelerated treatment schedule.

KW - concomitant boost radiotherapy

KW - head and neck tumors

KW - primary site

UR - http://www.scopus.com/inward/record.url?scp=0028298203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028298203&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 135

EP - 138

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -